📊 TNDM Key Takeaways
Is Tandem Diabetes Care Inc. (TNDM) a Good Investment?
Tandem Diabetes Care generates solid revenue growth (7.9% YoY) and maintains respectable 55.3% gross margins, but the company remains unprofitable at the operating level (-$17.4M) with minimal free cash flow ($4.8M or 1.9% margin). Most critically, the company carries unsustainable leverage at 4.54x Debt/Equity ratio ($601.8M debt against only $132.4M equity), creating severe financial distress risk that outweighs modest revenue gains.
Tandem Diabetes Care Inc. Key Strengths (TNDM)
- Strong gross margin of 55.3% demonstrates competitive positioning and pricing power in medical devices
- Consistent revenue growth of 7.9% YoY indicates steady market demand for diabetes management products
- Excellent short-term liquidity with current ratio of 3.58x and $179.3M cash provides near-term operational buffer
TNDM Stock Risks: Tandem Diabetes Care Inc. Investment Risks
- Operating losses of -$17.4M and net losses of -$20.4M show core business is unprofitable despite $247.2M revenue
- Extreme leverage with 4.54x Debt/Equity ratio ($601.8M long-term debt vs $132.4M stockholders equity) is unsustainable and limits financial flexibility
- Minimal free cash flow generation of only $4.8M (1.9% FCF margin) insufficient to service debt obligations without equity dilution or asset sales
Key Metrics to Watch
- Operating margin trajectory - must achieve profitability to justify debt load
- Free cash flow generation and sustainability - critical for debt service capability
- Debt refinancing risk and covenant compliance - high leverage limits future financing options
Tandem Diabetes Care Inc. (TNDM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 1.9% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.58x current ratio provides a solid financial cushion.
TNDM Profit Margin, ROE & Profitability Analysis
TNDM vs Healthcare Sector: How Tandem Diabetes Care Inc. Compares
How Tandem Diabetes Care Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tandem Diabetes Care Inc. Stock Overvalued? TNDM Valuation Analysis 2026
Based on fundamental analysis, Tandem Diabetes Care Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tandem Diabetes Care Inc. Balance Sheet: TNDM Debt, Cash & Liquidity
TNDM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tandem Diabetes Care Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.43 indicates the company is currently unprofitable.
TNDM Revenue Growth, EPS Growth & YoY Performance
TNDM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $234.4M | -$20.4M | $-0.30 |
| Q3 2025 | $244.0M | -$21.2M | $-0.31 |
| Q2 2025 | $221.9M | -$30.8M | $-0.47 |
| Q1 2025 | $191.7M | -$42.7M | $-0.65 |
| Q3 2024 | $185.6M | -$23.3M | $-0.35 |
| Q2 2024 | $195.9M | -$30.8M | $-0.47 |
| Q1 2024 | $169.4M | -$42.7M | $-0.65 |
| Q3 2023 | $185.6M | -$33.0M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tandem Diabetes Care Inc. Dividends, Buybacks & Capital Allocation
TNDM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tandem Diabetes Care Inc. (CIK: 0001438133)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 22, 2026 | 4 | xslF345X06/wk-form4_1779500208.xml | View → |
| May 22, 2026 | 4 | xslF345X06/wk-form4_1779480786.xml | View → |
| May 22, 2026 | 4 | xslF345X06/wk-form4_1779480707.xml | View → |
| May 22, 2026 | 4 | xslF345X06/wk-form4_1779480632.xml | View → |
| May 22, 2026 | 4 | xslF345X06/wk-form4_1779480532.xml | View → |
❓ Frequently Asked Questions about TNDM
What is the AI rating for TNDM?
Tandem Diabetes Care Inc. (TNDM) has an AI grade of C with 76% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNDM's key strengths?
Claude: Strong gross margin of 55.3% demonstrates competitive positioning and pricing power in medical devices. Consistent revenue growth of 7.9% YoY indicates steady market demand for diabetes management products.
What are the risks of investing in TNDM?
Claude: Operating losses of -$17.4M and net losses of -$20.4M show core business is unprofitable despite $247.2M revenue. Extreme leverage with 4.54x Debt/Equity ratio ($601.8M long-term debt vs $132.4M stockholders equity) is unsustainable and limits financial flexibility.
What is TNDM's revenue and growth?
Tandem Diabetes Care Inc. reported revenue of $247.2M.
Does TNDM pay dividends?
Tandem Diabetes Care Inc. does not currently pay dividends.
Where can I find TNDM SEC filings?
Official SEC filings for Tandem Diabetes Care Inc. (CIK: 0001438133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNDM's EPS?
Tandem Diabetes Care Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TNDM's fundamental grade?
Based on our AI fundamental analysis in June 2026, Tandem Diabetes Care Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TNDM stock overvalued or undervalued?
Valuation metrics for TNDM: ROE of -15.4% (sector avg: 15%), net margin of -8.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TNDM's AI grade for 2026?
Our dual AI analysis gives Tandem Diabetes Care Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNDM's free cash flow?
Tandem Diabetes Care Inc.'s operating cash flow is $11.1M, with capital expenditures of $6.3M. FCF margin is 1.9%.
How does TNDM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.2% (avg: 12%), ROE -15.4% (avg: 15%), current ratio 3.58 (avg: 2).
Is Tandem Diabetes Care Inc. carrying too much debt?
TNDM has a debt-to-equity ratio of 4.54x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.58 suggests adequate short-term liquidity.